{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:04:36Z","timestamp":1792253076344,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,3,15]],"date-time":"2015-03-15T00:00:00Z","timestamp":1426377600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s00280-015-2694-y","type":"journal-article","created":{"date-parts":[[2015,3,14]],"date-time":"2015-03-14T13:55:08Z","timestamp":1426341308000},"page":"993-1004","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer"],"prefix":"10.1007","volume":"75","author":[{"given":"Niall","family":"Tebbutt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusan","family":"Kotasek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard A.","family":"Burris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee S.","family":"Schwartzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas J.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Pang","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,15]]},"reference":[{"key":"2694_CR1","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2013) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. GLOBOCAN 2012 v10, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] Lyon, France: International Agency for Research on Cancer. http:\/\/globocan.iarc.fr , accessed on 13\/12\/2013"},{"key":"2694_CR2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11\u201330","journal-title":"CA Cancer J Clin"},{"key":"2694_CR3","unstructured":"NCCN (2014) National Comprehensive Cancer Care Network Clinical Practice Guidelines in Oncology\u2122: colorectal cancer. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf . Version 2.2015"},{"key":"2694_CR4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clcc.2011.06.012","volume":"10","author":"AS Lucas","year":"2011","unstructured":"Lucas AS, O\u2019Neil BH, Goldberg RM (2011) A decade of advances in cytotoxic chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer 10:238\u2013244","journal-title":"Clin Colorectal Cancer"},{"key":"2694_CR5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1586\/era.13.37","volume":"13","author":"TJ Price","year":"2013","unstructured":"Price TJ, Segelov E, Burge M, Haller DG, Ackland SP, Tebbutt NC et al (2013) Current opinion on optimal treatment for colorectal cancer. Expert Rev Anticancer Ther 13:597\u2013611","journal-title":"Expert Rev Anticancer Ther"},{"key":"2694_CR6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.clcc.2011.04.001","volume":"10","author":"VK Jain","year":"2011","unstructured":"Jain VK, Hawkes EA, Cunningham D (2011) Integration of biologic agents with cytotoxic chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer 10:245\u2013257","journal-title":"Clin Colorectal Cancer"},{"key":"2694_CR7","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1093\/annonc\/mds236","volume":"23","author":"HJ Schmoll","year":"2012","unstructured":"Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K et al (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23:2479\u20132516","journal-title":"Ann Oncol"},{"key":"2694_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clcc.2011.05.005","volume":"11","author":"E Chu","year":"2012","unstructured":"Chu E (2012) An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer 11:1\u201313","journal-title":"Clin Colorectal Cancer"},{"key":"2694_CR9","doi-asserted-by":"crossref","first-page":"8715","DOI":"10.1158\/0008-5472.CAN-05-4665","volume":"66","author":"A Polverino","year":"2006","unstructured":"Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L et al (2006) AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 66:8715\u20138721","journal-title":"Cancer Res"},{"key":"2694_CR10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa075853","volume":"359","author":"SI Sherman","year":"2008","unstructured":"Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG et al (2008) Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31\u201342","journal-title":"N Engl J Med"},{"key":"2694_CR11","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.2008.18.7815","volume":"27","author":"MJ Schlumberger","year":"2009","unstructured":"Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD et al (2009) Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794\u20133801","journal-title":"J Clin Oncol"},{"key":"2694_CR12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00280-010-1431-9","volume":"68","author":"RS Benjamin","year":"2011","unstructured":"Benjamin RS, Schoffski P, Hartmann JT, Van Oosterom A, Bui BN, Duyster J et al (2011) Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol 68:69\u201377","journal-title":"Cancer Chemother Pharmacol"},{"key":"2694_CR13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/1078-0432.CCR-09-1675","volume":"16","author":"GR Blumenschein Jr","year":"2010","unstructured":"Blumenschein GR Jr, Reckamp K, Stephenson GJ, O\u2019Rourke T, Gladish G, McGreivy J et al (2010) Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin\/paclitaxel and\/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res 16:279\u2013290","journal-title":"Clin Cancer Res"},{"key":"2694_CR14","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/annonc\/mdq731","volume":"22","author":"GR Blumenschein Jr","year":"2011","unstructured":"Blumenschein GR Jr, Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT et al (2011) A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 22:2057\u20132067","journal-title":"Ann Oncol"},{"key":"2694_CR15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1470-2045(11)70037-7","volume":"12","author":"M Martin","year":"2011","unstructured":"Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L et al (2011) Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 12:369\u2013376","journal-title":"Lancet Oncol"},{"key":"2694_CR16","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1200\/JCO.2011.41.4987","volume":"30","author":"GV Scagliotti","year":"2012","unstructured":"Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F et al (2012) International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin\/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 30:2829\u20132836","journal-title":"J Clin Oncol"},{"key":"2694_CR17","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"E Cutsem Van","year":"2007","unstructured":"Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658\u20131664","journal-title":"J Clin Oncol"},{"key":"2694_CR18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3816\/CCC.2006.n.008","volume":"5","author":"Z Wainberg","year":"2006","unstructured":"Wainberg Z, Hecht JR (2006) A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. Clin Colorectal Cancer 5:363\u2013367","journal-title":"Clin Colorectal Cancer"},{"key":"2694_CR19","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706\u20134713","journal-title":"J Clin Oncol"},{"key":"2694_CR20","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697\u20134705","journal-title":"J Clin Oncol"},{"issue":"21","key":"2694_CR21","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","volume":"32","author":"LS Schwartzberg","year":"2014","unstructured":"Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR et al (2014) PEAK: A randomized, multicenter phase II study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS Exon 2 metastatic colorectal cancer. J Clin Oncol 32(21):2240\u20132247. doi: 10.1200\/JCO.2013.53.2473","journal-title":"J Clin Oncol"},{"key":"2694_CR22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1541-7786.MCR-06-0404","volume":"5","author":"J Tabernero","year":"2007","unstructured":"Tabernero J (2007) The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5:203\u2013220","journal-title":"Mol Cancer Res"},{"key":"2694_CR23","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1200\/JCO.2008.19.8135","volume":"27","author":"JR Hecht","year":"2009","unstructured":"Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D et al (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27:672\u2013680","journal-title":"J Clin Oncol"},{"key":"2694_CR24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa0808268","volume":"360","author":"J Tol","year":"2009","unstructured":"Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563\u2013572","journal-title":"N Engl J Med"},{"key":"2694_CR25","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1200\/JCO.2007.11.6582","volume":"25","author":"RJ Mayer","year":"2007","unstructured":"Mayer RJ (2007) Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol 25:4165\u20134167","journal-title":"J Clin Oncol"},{"key":"2694_CR26","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1634\/theoncologist.2008-0108","volume":"13","author":"RS Herbst","year":"2008","unstructured":"Herbst RS, Sandler A (2008) Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. Oncologist 13:1166\u20131176","journal-title":"Oncologist"},{"key":"2694_CR27","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1200\/JCO.2007.12.0949","volume":"25","author":"LB Saltz","year":"2007","unstructured":"Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM et al (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25:4557\u20134561","journal-title":"J Clin Oncol"},{"key":"2694_CR28","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2010.29.5436","volume":"29","author":"E Cutsem Van","year":"2011","unstructured":"Van Cutsem E, Bajetta E, Valle J, Kohne CH, Hecht JR, Moore M et al (2011) Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787\/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 29:2004\u20132010","journal-title":"J Clin Oncol"},{"key":"2694_CR29","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1200\/JCO.2012.42.5355","volume":"30","author":"HJ Schmoll","year":"2012","unstructured":"Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL et al (2012) Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol 30:3588\u20133595","journal-title":"J Clin Oncol"},{"key":"2694_CR30","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2010.29.4496","volume":"29","author":"JR Hecht","year":"2011","unstructured":"Hecht JR, Trarbach T, Hainsworth JD, Major P, Jager E, Wolff RA et al (2011) Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787\/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 29:1997\u20132003","journal-title":"J Clin Oncol"},{"key":"2694_CR31","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/1471-2407-13-242","volume":"13","author":"LS Rosen","year":"2013","unstructured":"Rosen LS, Lipton L, Price TJ, Belman ND, Boccia RV, Hurwitz HI et al (2013) The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. BMC Cancer 13:242","journal-title":"BMC Cancer"},{"key":"2694_CR32","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2214\/AJR.11.7432","volume":"199","author":"SA Howard","year":"2012","unstructured":"Howard SA, Krajewski KM, Thornton E, Jagannathan JP, O\u2019Regan K, Cleary J et al (2012) Decade of molecular targeted therapy: abdominal manifestations of drug toxicities\u2014what radiologists should know. AJR Am J Roentgenol 199:58\u201364","journal-title":"AJR Am J Roentgenol"},{"key":"2694_CR33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14:29\u201337","journal-title":"Lancet Oncol"},{"key":"2694_CR34","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013\u20132019","journal-title":"J Clin Oncol"},{"key":"2694_CR35","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Cutsem Van","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499\u20133506","journal-title":"J Clin Oncol"},{"key":"2694_CR36","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1634\/theoncologist.2012-0190","volume":"17","author":"JC Bendell","year":"2012","unstructured":"Bendell JC, Bekaii-Saab TS, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H et al (2012) Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist 17:1486\u20131495","journal-title":"Oncologist"},{"key":"2694_CR37","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdp233","volume":"20","author":"E Cutsem Van","year":"2009","unstructured":"Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20:1842\u20131847","journal-title":"Ann Oncol"},{"key":"2694_CR38","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1002\/cncr.28112","volume":"119","author":"JR Infante","year":"2013","unstructured":"Infante JR, Reid TR, Cohn AL, Edenfield WJ, Cescon TP, Hamm JT et al (2013) Axitinib and\/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study. Cancer 119:2555\u20132563","journal-title":"Cancer"},{"key":"2694_CR39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/bjc.2013.20","volume":"108","author":"HS Hochster","year":"2013","unstructured":"Hochster HS (2013) HORIZON I: is there a future for oral anti-angiogenics on the horizon of colorectal cancer therapy? Br J Cancer 108:477\u2013478","journal-title":"Br J Cancer"},{"key":"2694_CR40","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303\u2013312","journal-title":"Lancet"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2694-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2694-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2694-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:11:45Z","timestamp":1559038305000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2694-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,15]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["2694"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2694-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,15]]}}}